CeriBell Inc

CBLL

Market cap $814M

CeriBell, Inc. (CBLL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Ceribell wins FDA Breakthrough status for its AI-driven EEG solution to detect and monitor LVO strokes in hospitals, boosting credibility and growth outlook.

SUNNYVALE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection monitor for patients in the hospital setting.

SUNNYVALE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Monday, January 12, 2026, at 9:00 am Pacific Standard Time / 12:00 pm Eastern Standard Time.

CeriBell gains FDA clearance for its continuous delirium monitoring solution, boosting its AI-driven EEG platform and expanding its role in critical care.

SUNNYVALE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its proprietary delirium monitoring solution,1 the first and only FDA cleared delirium screening and monitoring device.

Becomes the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults enabling rapid bedside detection, diagnosis, and treatment of non-convulsive seizures Becomes the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults enabling rapid bedside detection, diagnosis, and treatment of non-convulsive seizures

SUNNYVALE, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Piper Sandler 37th Annual Healthcare Conference in New York. The presentation will take place on Wednesday, December 3, 2025, at 6:10 a.m. Pacific Standard Time / 9:10 a.m. Eastern Standard Time.

SUNNYVALE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York.

CeriBell, Inc. ( CBLL ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Xingjuan Chao - Co-Founder, President, CEO & Director Scott Blumberg - Chief Financial Officer Conference Call Participants Travis Steed - BofA Securities, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Brandon Vazquez - William Blair & Company L.L.C., Research Division Joshua Jennings - TD Cowen, Research Division William Plovanic - Canaccord Genuity Corp., Research Division Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Good afternoon, and thank you all for participating in today's call.